Clairvoyant Therapeutics: Clairvoyant's Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
VANCOUVER, BC / ACCESSWIRE / October 13, 2022 / Clairvoyant Therapeutics ("Clairvoyant"), a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction